ONE-IBC-GROUP
One IBC Group , an international corporate service provider with 12 years of experience and a global outreach, highlighted in its 2022 action plan that technology is going to be the company’s main focus of growth. Through digital transformation and innovation, One IBC Group believes not only its services and operations will drastically improve, but the whole industry will also benefit and change the way it traditionally works.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005053/en/
The quest for digital transformation
In recent years, a majority of businesses have shifted their focus on technology and innovation in order to improve operational efficiency and further connect their services to their customers. With the help of revolutionary technologies such as CRMs, mobile apps, websites, etc., businesses have now been able to simplify their operations, tailor their products and services, and adapt to the various needs of their clients.
With that being said, not every industry can embark on the digitalized trend as quickly. Corporate service is a good example. Most, if not all, corporate service providers on the market right now are still using the same technology of 20 years ago. Though the services can be processed entirely remotely, and some can even be done automatically, no significant change has been made since then, while customer demand is increasing from time to time.
For an industry that has so much potential for digital transformation, corporate service is looking for a game-changing breakthrough.
One IBC Group’s plan to innovate
Since it was founded, One IBC Group has been using technology to remotely provide corporate services around the world. To be able to grow faster and compete with big players in the industry, the company decided to focus more on technology development.
In its 2022 action plan, One IBC Group emphasizes that digital transformation and innovation will be its primary mission. The plan set out a 5-year roadmap pinpointing each goal that needed to be achieved in a set time to upgrade the system and apply new technology. It includes automating the service order process, optimizing the operation procedures, building a client portal, incorporating software-as-a-service (SaaS) platforms, and constantly updating the whole system.
“It is no longer the future. The race for innovation is the new norm now,” said Jimmy Lee, CEO of One IBC Group. “With a solid technology foundation that we are having now, we believe One IBC Group can make a revolution in the corporate service industry.”
Prior to that, in 2021, One IBC Group had introduced its first mobile app . It was created with the goal of enhancing and improving client experience as well as introducing a new way to set up overseas businesses.
“This is just the beginning,” Jimmy said. “We are trying to provide more services and integrate them into our platforms as part of our ongoing development and extension, at the same time create a whole ecosystem for businesses to build their global expansion strategies.”
About One IBC Group
One IBC Group is a leading corporate service provider with global experience and delivery capabilities.
Since its beginning, One IBC Group has strived to provide global expansion strategies to entrepreneurs, investors, and business owners worldwide, with services ranging from company formation , trademark and license registration , to office and secretarial services. It has been building connections with international partners and using advanced technology to provide the best services to its clients.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005053/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
